IGF2BP2 and early-onset autosomal dominant Alzheimer disease: Deng et al. showed that IGF2BP2 can bind to mRNA in an m6A-dependent manner and thus has the potential to become a new diagnostic and therapeutic target for patients with Alzheimer's disease (52).